• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
PMV Pharmaceuticals, Inc. (PMVP) Stock Price, News & Analysis

PMV Pharmaceuticals, Inc. (PMVP) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.62

$0.05

(2.87%)

Day's range
$1.56
Day's range
$1.65
50-day range
$1.45
Day's range
$1.82
  • Country: US
  • ISIN: US69353Y1038
52 wk range
$1.4
Day's range
$3.47
  • CEO: Dr. David H. Mack Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.47
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (PMVP)
  • Company PMV Pharmaceuticals, Inc.
  • Price $1.62
  • Changes Percentage (2.87%)
  • Change $0.05
  • Day Low $1.56
  • Day High $1.65
  • Year High $3.47

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $15.50
  • High Stock Price Target $36.00
  • Low Stock Price Target $5.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.32
  • Trailing P/E Ratio -1.26
  • Forward P/E Ratio -1.26
  • P/E Growth -1.26
  • Net Income $-68,960,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

PMV Pharmaceuticals, Inc. Frequently Asked Questions

  • What is the PMV Pharmaceuticals, Inc. stock price today?

    Today's price of PMV Pharmaceuticals, Inc. is $1.62 — it has increased by +2.87% in the past 24 hours. Watch PMV Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does PMV Pharmaceuticals, Inc. release reports?

    Yes, you can track PMV Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the PMV Pharmaceuticals, Inc. stock forecast?

    Watch the PMV Pharmaceuticals, Inc. chart and read a more detailed PMV Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is PMV Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by PMV Pharmaceuticals, Inc. stock ticker.

  • How to buy PMV Pharmaceuticals, Inc. stocks?

    Like other stocks, PMVP shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is PMV Pharmaceuticals, Inc.'s EBITDA?

    PMV Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in PMV Pharmaceuticals, Inc.’s financial statements.

  • What is the PMV Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in PMV Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including PMV Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. PMV Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for PMV Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review PMV Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.